<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03932006</url>
  </required_header>
  <id_info>
    <org_study_id>[2015]2-159</org_study_id>
    <nct_id>NCT03932006</nct_id>
  </id_info>
  <brief_title>A Multicenter，Double-Blind and Randomized Controlled Trial of Fengshigutong Capsule in the Treatment of Ankylosing Spondylitis</brief_title>
  <official_title>A Multicenter，Double-Blind and Randomized Controlled Trial of Fengshigutong Capsule in the Treatment of Ankylosing Spondylitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, double-blind, multicentral clinical trial to investigate the efficacy
      and safety of Fengshigutong Capsule in the treatment of active ankylosing spondylitis(AS).
      The primary purpose is to assess the different maintaining treatment programme in AS patients
      with controlled inflammation by Imrecoxib. The trial will include 180 patients who will be
      divided into three group: Fengshigutong Capsule plus Imrecoxib group, Imrecoxib group and
      Fengshigutong Capsule group. Patients will complete the 4-week therapy.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 30, 2016</start_date>
  <completion_date type="Anticipated">May 31, 2019</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the proportions of patients reaching Assessment in Ankylosing Spondylitis 20%</measure>
    <time_frame>4 week</time_frame>
    <description>ASAS20 was defined as an improvement of ≥20% and absolute improvement of ≥1 unit (0-10-cm VAS) from baseline in ≥3 of the following 4 domains (and absence of deterioration in any domain): patient's global assessment of disease activity (PTGA), pain assessment (mean of total and nocturnal pain scores), Bath Ankylosing Spondylitis Functional Index (BASFI), and clinical inflammation (mean of 2 morning stiffness-related scores on the BASDAI)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>the proportions of patients reaching Assessment in Ankylosing Spondylitis 50%</measure>
    <time_frame>4 week</time_frame>
    <description>defined as 20% improvement in 5 of the following 6 domains: PTGA, pain assessment, BASFI, clinical inflammation, spinal mobility, and C-reactive protein (CRP)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ASAS20 response</measure>
    <time_frame>4 week</time_frame>
    <description>ASAS20 was defined as an improvement of ≥20% and absolute improvement of ≥1 unit (0-10-cm VAS) from baseline in ≥3 of the following 4 domains (and absence of deterioration in any domain): patient's global assessment of disease activity (PTGA), pain assessment (mean of total and nocturnal pain scores), Bath Ankylosing Spondylitis Functional Index (BASFI), and clinical inflammation (mean of 2 morning stiffness-related scores on the BASDAI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ASAS5/6 response</measure>
    <time_frame>4 week</time_frame>
    <description>defined as 20% improvement in 5 of the following 6 domains: PTGA, pain assessment, BASFI, clinical inflammation, spinal mobility, and C-reactive protein (CRP)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Ankylosing Spondylitis</condition>
  <arm_group>
    <arm_group_label>Fengshigutong Capsule plus Imrecoxib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fengshigutong Capsule 1.2g twice a day,Imrecoxib 0.1g twice a day,orally</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fengshigutong Capsule</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fengshigutong Capsule 1.2g twice a day,orally</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Imrecoxib</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Imrecoxib 0.1g twice a day,orally</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fengshigutong Capsule plus Imrecoxib</intervention_name>
    <description>Fengshigutong Capsule 1.2g twice a day,Imrecoxib 0.1g twice a day,orally</description>
    <arm_group_label>Fengshigutong Capsule plus Imrecoxib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fengshigutong Capsule</intervention_name>
    <description>Fengshigutong Capsule 1.2g twice a day,orally</description>
    <arm_group_label>Fengshigutong Capsule</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Imrecoxib</intervention_name>
    <description>Imrecoxib 0.1g twice a day,orally</description>
    <arm_group_label>Imrecoxib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 to 65 years

          -  Meet 1984 modified New York criteria for AS

          -  The Bath AS Disease Activity Index (BASDAI) ≥4 on a 0-10-cm visual analog scale or the
             Ankylosing Spondylitis Disease Activity Score using the C-reactive protein level
             (ASDAS-CRP) ≥1.3

          -  NSAIDs washout period of at least 7 days prior to randomization

          -  DMARDs washout period of at least 4 weeks prior to randomization

          -  Corticosteroids washout period of at least 2 weeks prior to randomization

          -  Biological agents washout period of at least 3 months prior to randomization.

        Exclusion Criteria:

          -  Peptic ulcer

          -  Unstable cardiac diseases

          -  Hematologic disorders

          -  Psychosis

          -  Malignancy

          -  Multiple sclerosis

          -  severe COPD

          -  fibromyalgia and other rheumatic disease

          -  Corticosteroids were injected into the articular cavity within 3 months

          -  Chinese medicine was taken within 28 days

          -  Pregnant and lactating women

          -  Alcohol and drug abuse

          -  Spinal cord compression
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jieruo Gu, Prof</last_name>
    <role>Study Director</role>
    <affiliation>Rheumatology Department, the Third Affiliated Hospital of Sun Yat-sen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jieruo Gu, Prof</last_name>
    <phone>+8620-85252055</phone>
    <email>gujieruo@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Rheumatology Department, the Third Affiliated Hospital of Sun Yat-sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jieruo Gu, Prof</last_name>
      <phone>+8620-85252055</phone>
      <email>gujieruo@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>April 26, 2019</study_first_submitted>
  <study_first_submitted_qc>April 26, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 30, 2019</study_first_posted>
  <last_update_submitted>April 26, 2019</last_update_submitted>
  <last_update_submitted_qc>April 26, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 30, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Gu Jieruo</investigator_full_name>
    <investigator_title>Division of Rheumatology of Third Affiliated Hospital of Sun Yat-sen University</investigator_title>
  </responsible_party>
  <keyword>ankylosing spondylitis</keyword>
  <keyword>Fengshigutong Capsule</keyword>
  <keyword>imrecoxib</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spondylitis</mesh_term>
    <mesh_term>Spondylitis, Ankylosing</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

